Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB
ECONOMY & POLICY

Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators.

He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries.

He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence.

He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators. He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries. He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence. He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Next Story
Infrastructure Transport

MMRDA advances 250 m on Orange Gate–Marine Drive tunnel

The Mumbai Metropolitan Region Development Authority (MMRDA) has completed 250 m of underground tunnelling for the Orange Gate–Marine Drive Urban Road Tunnel using India’s largest slurry shield tunnel boring machine (TBM) deployed for an urban road project.The project involves twin tunnels extending over 7 km beneath critical transport corridors, including Central Railway, Western Railway and Metro Line 3. The work requires high-precision engineering to navigate densely developed urban infrastructure.Once completed, the tunnel is expected to reduce travel time between Orange Gate and Marin..

Next Story
Infrastructure Urban

Hindustan Zinc Pays Rs 188.46 Billion in FY26

Hindustan Zinc contributed Rs 188.46 billion to the public exchequer in FY 2025-26, according to its 9th Tax Transparency Report. The contribution, equivalent to 46 per cent of the company’s revenue, included direct and indirect taxes, government royalties, dividends to the Government of India, withholding taxes and other statutory levies.The company’s five-year cumulative contribution to the exchequer stood at Rs 915.72 billion. In FY26, Hindustan Zinc reported revenue of Rs 408.44 billion, EBITDA of Rs 221.62 billion and profit after tax of Rs 138.32 billion. It also achieved its highest..

Next Story
Infrastructure Urban

World of Concrete India 2026 Opens in Mumbai

Informa Markets in India will host the 12th edition of World of Concrete India 2026 from 3–5 June 2026 at the Bombay Exhibition Centre, Mumbai. The specialised B2B exhibition will bring together manufacturers, suppliers, contractors, developers, architects, consultants, infrastructure companies, project leaders and government stakeholders.The event is expected to feature over 350 brands and more than 18,000 trade professionals. It will cover concrete and cement, dry mortar, precast technologies, formwork, construction chemicals, industrial and commercial flooring, scaffolding, safety solutio..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement